CARMIEL, Israel, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) and (TASE:PLX), announced today that the Company will participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposiumTM 2016. The details are as follows:
SunTrust Robison Humphrey Orphan Drug Day
February 23, 2016
JW Marriott Essex House, New York City, NY
12th Annual WORLDSymposiumTM 2016
February 29 – March 4, 2016
Manchester Grand Hyatt, San Diego, CA
Oral presentation: “Novel treatment for Fabry disease: IV administration of plant derived alpha-GAL-A enzyme safety and efficacy interim report,” to be presented by Dr. Derralynn Hughes of the Lysosomal Storage Disease Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK, and a principal investigator in the Company’s clinical trial of PRX-102 for the treatment of Fabry disease. The oral presentation will be given at 3:15 PM PT on Thursday, March 3, 2016.
Poster #138: “PRX-102 α-Galactosidase-A (peguniglasidase alfa) -- Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease.”
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a pegylated version of a recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-106, an orally-delivered anti-inflammatory treatment; PRX-110, a chemically modified DNase I for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 firstname.lastname@example.org
Source:Protalix BioTherapeutics, Inc.